Paris-based Lucis has secured $20 million in a Series A funding round led by venture capital firm Singular to scale its AI-powered preventive health platform. The investment is set to accelerate the company's expansion across Europe, signaling growing investor confidence in proactive, data-driven healthcare models. This funding positions Lucis to address chronic illness by focusing on early detection and personalized intervention.
A New Approach to Proactive Healthcare
Lucis offers a platform that analyzes over 110 blood biomarkers to provide a comprehensive overview of an individual's health status. Its system uses artificial intelligence to generate personalized guidance on nutrition, lifestyle, and supplementation based on longitudinal data. Crucially, every recommendation is reviewed and verified by a physician to ensure clinical validity and user safety.
Singular's Strategic Bet on Health Infrastructure
The investment marks a significant move for Singular, a firm renowned for its successful bets on SaaS and fintech infrastructure companies like Algolia and Qonto. The firm is applying its established thesis of backing platforms with a "compounding data advantage" to the preventive health sector. Singular views Lucis as building the foundational data layer that will define the future of proactive healthcare in Europe.
Jeremy Uzan, a founding partner at Singular, emphasized that Lucis combines clinical credibility with AI at scale, positioning it as a clear category winner. He highlighted the company's rapid user acquisition and measurable health outcomes as key differentiators. This investment underscores Singular's belief that health data represents the next major infrastructure category for venture capital.
Demonstrating Early Clinical Impact
With a user base of 10,000, Lucis has already demonstrated promising results from its proactive model. Early data shows that 75% of users improved at least three key health markers within six months without medication. This success is further supported by a high engagement rate, with over 80% of users choosing to retest.
The platform has processed over one million biomarker tests, revealing that nearly all initial users discovered at least one biomarker outside of optimal ranges. This highlights a significant unmet need for early detection and intervention in the general population. These metrics provide tangible evidence for the platform's effectiveness and its potential to shift healthcare from reactive treatment to prevention.
Navigating a Growing Market
Lucis enters a global preventive healthcare market projected to exceed $1 trillion by 2035, driven by the rising burden of chronic disease. While the US has seen rapid growth with companies like Function Health, the European landscape is still emerging. Lucis differentiates itself from competitors by focusing on longitudinal blood biomarker tracking with deep clinical integration.
Fueling European Expansion
The new capital, which brings Lucis's total funding to $28 million, will be used to drive expansion into new markets. The company currently operates in France, the UK, Ireland, and Portugal, with plans to launch in Spain, Germany, and Italy by the end of 2026. This strategic growth will involve scaling its AI platform and strengthening its clinical and operational infrastructure.
This $20 million investment provides Lucis with the resources to solidify its position as a leader in Europe's burgeoning preventive health sector. By combining AI-driven insights with rigorous clinical oversight, the company is poised to make proactive health management more accessible. The success of this model could significantly influence the broader healthcare industry's transition toward a more sustainable, prevention-focused future.